Skip to main content
Telo Genomics Corp. logo

Telo Genomics Corp. — Investor Relations & Filings

Ticker · TELO TSXV Professional, scientific and technical activities
Open in API
Filings indexed 198 across all filing types
Latest filing 2025-08-05 Regulatory Filings
Country CA Canada
Listing TSXV TELO

About Telo Genomics Corp.

https://www.telodx.com/

Telo Genomics Corp. is a molecular diagnostics company specializing in developing predictive and prognostic solutions utilizing its proprietary telomere-based platform. The core technology, TeloView®, quantifies genomic instability by measuring the 3D structure and spatial organization of telomeres. This platform is designed to provide actionable information regarding disease aggressiveness and potential response to treatment, helping to tailor therapeutic approaches. Applications focus primarily on multiple cancers (oncology) and neurodegenerative diseases (CNS). The company is pioneering the most comprehensive telomere platform in the industry to address unmet market needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press‐release style announcement stating that Telo Genomics will present at an OTCQB Venture Virtual Investor Conference. It does not contain actual presentation slides or detailed financial disclosures, nor is it a formal earnings release, management change, proxy, dividend notice, or any other specific report type. It does not attach a report but simply announces participation in an investor event. Therefore it does not fit the more specific categories and falls under the general “Regulatory Filings” fallback category.
2025-08-05 English
Report of exempt distribution (45-106F1).pdf
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory form (Form 45-106F1) filed under NI 45-106 to report an exempt distribution of securities (common shares). It provides detailed information on the number of shares issued, pricing, purchasers, and proceeds—i.e., a share issuance event under a regulatory exemption. The most specific matching category is Share Issue/Capital Change (SHA), which covers announcements and documents regarding new share issues and other capital changes.
2025-07-22 English
News release - English.pdf
Legal Proceedings Report Classification · 1% confidence The document is a corporate press release discussing a lawsuit filed by the company’s former President and the company’s intention to file a statement of defence and counterclaim. It provides an update on legal proceedings rather than financial results, share transactions, dividend notices, or governance changes. This directly aligns with the definition of a Legal Proceedings Report (LTR).
2025-07-01 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing initiation of a clinical trial and describing the company’s technology, markets, and forward-looking statements. It contains no financial results, regulatory form references, dividend or voting declarations, margin call, share issuance, or governance materials. It is a general corporate update rather than a formal investor presentation or detailed financial/annual/interim report. Therefore, it falls under the fallback category: Regulatory Filings (RNS).
2025-06-18 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the CFO, which is a compliance certificate that accompanies interim financial statements and MD&A under Canadian NI 52-109. It is not the interim report itself (no financial tables or MD&A text), nor an announcement of a report release, dividend, or corporate action. There is no specific category for a certification form, so this is a general regulatory filing. Therefore, the most appropriate classification is RNS (General Regulatory Filing).
2025-05-27 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” under Canadian NI 52-109, signed by the CEO, certifying the interim financial report and MD&A. It is not the interim report itself (which would contain financial statements and MD&A), nor is it an announcement of a report publication. It is a standalone regulatory certificate filed with securities regulators, fitting the fallback category “Regulatory Filings.”
2025-05-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.